KovaDx is a brand that aims to remove barriers to quality care through point-of-care blood monitoring. They are deeply committed to addressing systemic injustices that prevent people from accessing healthcare, regardless of their income, race, gender, or any other circumstances of birth. Their focus begins with Sickle Cell Disease (SCD), where they utilize their proprietary 3D phase imaging microscope and deep learning algorithms to empower patients and their providers in taking a proactive approach to managing their health.

KovaDx is developing a tool that enables ongoing monitoring and preventative care for individuals with rare blood diseases. Their device utilizes 3D Quantitative Phase Imaging (QPI) to obtain data about human red blood cells and create a Red Blood Cell Health Index. By bridging the divide and increasing access to affordable and accurate diagnostics, KovaDx aims to decrease childhood mortality in low-income countries and significantly improve the quality of life for individuals with Sickle Cell Disease.

Driven by recent investments in health equity and access, the brand also recognizes the potential of decentralized models of care and the advances in AI technology that enable the processing of large amounts of data. With a pipeline that includes Sickle Cell Disease, rare blood diseases, Thalassemia, G6PD, and blood cancers like Multiple Myeloma and Leukemia, KovaDx is positioned to contribute to the evolving pharmacotherapeutic landscape and drive much-needed research in these areas. Connect with KovaDx today to learn more and be a part of their mission to make quality healthcare accessible to all